Cargando…
Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins
The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric dr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076460/ https://www.ncbi.nlm.nih.gov/pubmed/32013056 http://dx.doi.org/10.3390/pharmaceutics12020106 |
_version_ | 1783507221897805824 |
---|---|
author | Janisova, Larisa Gruzinov, Andrey Zaborova, Olga V. Velychkivska, Nadiia Vaněk, Ondřej Chytil, Petr Etrych, Tomáš Janoušková, Olga Zhang, Xiaohan Blanchet, Clement Papadakis, Christine M. Svergun, Dmitri I. Filippov, Sergey K. |
author_facet | Janisova, Larisa Gruzinov, Andrey Zaborova, Olga V. Velychkivska, Nadiia Vaněk, Ondřej Chytil, Petr Etrych, Tomáš Janoušková, Olga Zhang, Xiaohan Blanchet, Clement Papadakis, Christine M. Svergun, Dmitri I. Filippov, Sergey K. |
author_sort | Janisova, Larisa |
collection | PubMed |
description | The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery. |
format | Online Article Text |
id | pubmed-7076460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70764602020-03-20 Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins Janisova, Larisa Gruzinov, Andrey Zaborova, Olga V. Velychkivska, Nadiia Vaněk, Ondřej Chytil, Petr Etrych, Tomáš Janoušková, Olga Zhang, Xiaohan Blanchet, Clement Papadakis, Christine M. Svergun, Dmitri I. Filippov, Sergey K. Pharmaceutics Article The binding of plasma proteins to a drug carrier alters the circulation of nanoparticles (NPs) in the bloodstream, and, as a consequence, the anticancer efficiency of the entire nanoparticle drug delivery system. We investigate the possible interaction and the interaction mechanism of a polymeric drug delivery system based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (pHPMA) with the most abundant proteins in human blood plasma—namely, human serum albumin (HSA), immunoglobulin G (IgG), fibrinogen (Fbg), and apolipoprotein (Apo) E4 and A1—using a combination of small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC), and nuclear magnetic resonance (NMR). Through rigorous investigation, we present evidence of weak interactions between proteins and polymeric nanomedicine. Such interactions do not result in the formation of the protein corona and do not affect the efficiency of the drug delivery. MDPI 2020-01-28 /pmc/articles/PMC7076460/ /pubmed/32013056 http://dx.doi.org/10.3390/pharmaceutics12020106 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Janisova, Larisa Gruzinov, Andrey Zaborova, Olga V. Velychkivska, Nadiia Vaněk, Ondřej Chytil, Petr Etrych, Tomáš Janoušková, Olga Zhang, Xiaohan Blanchet, Clement Papadakis, Christine M. Svergun, Dmitri I. Filippov, Sergey K. Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title | Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title_full | Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title_fullStr | Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title_full_unstemmed | Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title_short | Molecular Mechanisms of the Interactions of N-(2-Hydroxypropyl)methacrylamide Copolymers Designed for Cancer Therapy with Blood Plasma Proteins |
title_sort | molecular mechanisms of the interactions of n-(2-hydroxypropyl)methacrylamide copolymers designed for cancer therapy with blood plasma proteins |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076460/ https://www.ncbi.nlm.nih.gov/pubmed/32013056 http://dx.doi.org/10.3390/pharmaceutics12020106 |
work_keys_str_mv | AT janisovalarisa molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT gruzinovandrey molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT zaborovaolgav molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT velychkivskanadiia molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT vanekondrej molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT chytilpetr molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT etrychtomas molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT janouskovaolga molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT zhangxiaohan molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT blanchetclement molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT papadakischristinem molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT svergundmitrii molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins AT filippovsergeyk molecularmechanismsoftheinteractionsofn2hydroxypropylmethacrylamidecopolymersdesignedforcancertherapywithbloodplasmaproteins |